PubMed Health⌕ Search

PubMed · 1140948

Ischemic heart disease and pulmonary ventilatory function.

Abstract

The results of spirometric examinations on 4, 331 Israeli male civil service employees, aged 45 years or more, were analyzed according to the presence or absence of certain aspects of ischemic heart disease. Vital capacity was lower in individuals with a previously history of a heart attack, in those with definite or suspected angina pectoris and in those with ECG evidence of myocardial ischemia, probable or possible myocardial infarction, left bundle branch block or nonspecific T wave changes in subjects without these findings. The differences were small, but statistically significant. Vital capacity was lower in subjects with a recent history of a heart attack (within three years) than in those whose heart attack had occurred more than three years prior to the examination. The ratio of forced expiratory volume in the first second to forced vital capacity was not significantly different between individuals with or without a past history of heart attack, angina pectoris or ECG evidence of coronary heart disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Z V Schlesinger, U Goldbourt, J H Medalie, N Neufeld, E Riss, D Oron. 1975. Ischemic heart disease and pulmonary ventilatory function.. https://pubmed.ncbi.nlm.nih.gov/1140948/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗